Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience
- 1 March 2021
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 192 (6), 1049-1053
- https://doi.org/10.1111/bjh.16946
Abstract
Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We analysed 33 patients who received ibrutinib, alone or with other therapies, for PCNSL (n = 9) or SCNSL (n = 24). The objective response rate was 58% (complete response 55%). The median progression-free survival and overall survival for patients with PCNSL were both 3 center dot 1 months; for SCNSL, 10 center dot 2 and 11 center dot 5 months respectively. Only one invasive fungal infection was observed, despite concurrent or recent use of dexamethasone 8-16 mg daily in 14 patients (42%). Ibrutinib has encouraging activity in these aggressive malignancies.Keywords
This publication has 15 references indexed in Scilit:
- Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) TrialBlood, 2019
- Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphomaEuropean Journal Of Cancer, 2018
- Primary CNS LymphomaJournal of Clinical Oncology, 2017
- High‐dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B‐cell lymphomaBritish Journal of Haematology, 2016
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaNature Medicine, 2015
- Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutationsBlood Cancer Journal, 2014
- Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomasHaematologica, 2012
- Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell LymphomaCancer Cell, 2012
- Oncogenically active MYD88 mutations in human lymphomaNature, 2010
- Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma CellsThe Journal of Experimental Medicine, 2001